Défis

As the organization scaled its vaccine portfolio and expanded field coverage, it became harder to sustain consistent scientific excellence across regions. Recognition and motivation were uneven, often delayed, and not tightly connected to measurable medical affairs outcomes.

• KOL engagement quality varied by territory: Relationship depth and follow-through were inconsistent across regions.
• Scientific exchange impact was hard to recognize at scale: Conference engagements and high-value medical information exchanges weren’t consistently celebrated.
• Clinical insights capture lacked standardization: Valuable field intelligence was collected inconsistently and wasn’t reliably rewarded.
• Evidence-generation contributions were under-recognized: Publication support and IIS enablement were often invisible compared to commercial metrics.
• Advisory board execution needed stronger accountability: Recruiting the right experts and ensuring productive boards required clearer incentives.
• Manual recognition processes created delays and governance risk: Inconsistent approvals and limited auditability reduced trust and slowed rewards.

Personas involved

• Medical Science Liaisons (MSLs): Build KOL relationships, deliver scientific exchange, capture insights, and enable evidence-generation activities.
• Medical Affairs Leadership: Define scientific excellence standards, governance, and outcomes tied to evidence and engagement.
• Therapeutic Area Heads / Medical Directors: Validate high-impact contributions (KOL outcomes, advisory boards, publications, IIS).
• Medical Operations & Compliance Teams: Ensure rewards and recognition follow policy, documentation, and approval requirements.
• Learning & Development Teams: Manage certification pathways and scientific training programs linked to field readiness.
• Program Admin / Super Admin: Configure Empuls awards, workflows, budgets, approval matrices, and reporting dashboards.

The solution

The manufacturer needed a structured, compliant, and scalable way to recognize scientific excellence—so MSLs stayed focused on outcomes that strengthen evidence, engagement, and therapy adoption.

Xoxoday Empuls delivered a centralized recognition and rewards framework that celebrated meaningful scientific contributions—using policy-led workflows, role-based approvals, and integrations with medical affairs systems to ensure recognition was timely, credible, and auditable.

KOL engagement excellence recognition: Xoxoday Empuls enabled leadership to recognize MSLs who built deep, productive KOL partnerships—tied to outcomes like advisory participation, research collaborations, and thought leadership contributions, not just meeting counts.

Scientific exchange recognition: MSLs received recognition for impactful scientific presentations, high-quality medical information responses, and meaningful conference interactions—creating momentum for peer-to-peer medical education excellence.

Clinical insights rewards for actionable intelligence: Xoxoday Empuls helped reward MSLs who captured high-value clinical insights from HCPs that informed medical affairs priorities, lifecycle strategies, and evidence planning—driving consistency in insight quality and submission discipline.

Publication support recognition: The program recognized teams and individuals who supported abstracts, posters, manuscripts, and congress submissions—encouraging proactive evidence dissemination across priority therapeutic areas.

Advisory board success incentives: Xoxoday Empuls enabled incentive frameworks for identifying and recruiting the right experts, ensuring strong attendance, and driving actionable outputs from advisory boards—reinforcing quality and preparedness.

Investigator-initiated study (IIS) support recognition: MSLs who identified promising IIS proposals and supported documentation, feasibility alignment, and follow-through were recognized—helping scale real-world evidence generation across regions.

Seamless integration with medical affairs systems for verified recognition: Xoxoday Empuls integrated with CRM/medical affairs platforms, LMS, event systems, and compliance workflows—so recognitions could be triggered based on verified activities (e.g., logged scientific exchange, completed certification, advisory board completion) and routed through approval matrices. This reduced manual work, strengthened governance, and improved the speed and transparency of recognition delivery.

Impact

• 34% increase in verified KOL engagement depth, driven by outcome-based recognition.
• 2.2× growth in documented scientific exchange activities, supported by timely celebration and visibility.
• 27% improvement in high-quality clinical insight submissions, improving downstream strategy inputs.
• 19% increase in advisory board effectiveness scores, driven by better expert fit and preparation incentives.
• 23% rise in publication support participation, accelerating evidence dissemination across priority areas.
• INR 78 crore in automated rewards and recognition value delivered annually, with improved timeliness, transparency, and governance.

Conclusion

By implementing Xoxoday Empuls, the vaccines & immuno-therapeutics manufacturer built a recognition-led culture for medical affairs that elevated the work MSLs do best—scientific partnership, credible exchange, and evidence generation. From KOL engagement and advisory boards to clinical insights and publications, Xoxoday Empuls enabled a scalable, compliant recognition framework that improved consistency across India, strengthened scientific impact, and reinforced excellence across the entire medical affairs ecosystem.